York, U.K.-based Abingdon Health plc reported that the AbC-19 rapid test for the detection of SARS-CoV-2 antibodies is now available for purchase by health care professionals on the Abingdon Health website. The AbC-19 rapid test is a self-contained, lateral flow immunoassay designed to give results within 20 minutes at the point of use. The test is designed to confirm the presence of IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus.
Mountain View, Calif.-based Alivecor Inc. reported a new collaboration with Cambridge, U.K.-based Astrazeneca plc to research new disease management solutions in cardiovascular, renal and metabolism (CVRM) therapeutic areas. The collaboration will translate Alivecor's potassium detection technology and science, which enables potassium measurement outside of blood draws, into real-world disease management applications and solutions.
Crystal Lake, Ill.-based Aptargroup Inc. reported that its Activ-Film technology was selected to protect a new SARS Rapid Antigen test for COVID-19 that recently received emergency use authorization from the U.S. FDA. The Quickvue SARS Antigen test is a point-of-care rapid antigen test developed by Quidel Corp. Aptar CSP Technologies’ Activ-Film technology is integrated into the diagnostic kit to protect against moisture and other environmental conditions that could otherwise impact test accuracy.
Ares Genetics GmbH, a Vienna, Austria-based subsidiary of Opgen Inc., reported the publication of a study introducing best practice techniques for prediction of antibiotic susceptibility testing (AST) results from whole-genome sequencing (WGS) data. The work assessed different machine learning techniques for WGS-based AST on several thousand genome assemblies across more than 50 species/compound combinations collated from public databases.
Vancouver, British Columbia-based Avricore Health Inc. signed a letter of intent with Avrok Laboratories LLC, a CLIA certified laboratory in California, to offer COVID-19 screening to travelers in the U.S., Canada, Mexico, and the Caribbean. Avricore and Avrok have organized a service offering which will deliver rapid antigen tests at prospective destination resorts under the oversight of Avrok. Results are then securely reported directly via Avricore’s Healthtab, a point-of-care screening system.
Garden City, N.Y.-based Beyond Air Inc. reported a funding agreement with the Cystic Fibrosis Foundation to advance the clinical development of high concentration nitric oxide (NO) for the treatment of nontuberculous mycobacteria (NTM) pulmonary disease. Under the terms of the agreement, Beyond Air will receive up to $2.17 million to help fund the company’s ongoing Lungfit GO NTM pilot study. The study is an at-home, 12-week, single arm, multicenter pilot trial in Australia, which is expected to enroll approximately 20 CF or non-CF bronchiectasis patients with refractory Mycobacterium avium complex (MAC) or Mycobacterium abscessus complex (MABSC) lung infections. Beyond Air expects to report interim data around the middle of calendar year 2021, which will be followed by topline data approximately six months later.
Atlanta-based Bioiq Inc. reported a partnership with Temple City, Calif.-based Fulgent Genetics Inc. to offer viral genome sequencing capable of identifying various variants of the COVID-19 virus. The partnership makes it possible for Bioiq employer, government and health plan customers to leverage Fulgent Genetics’ testing solution to inform testing regimens, clinical treatment protocols and vaccination strategies pursuant to the identified COVID-19 variant. Local public health agencies can similarly leverage the testing solution in ongoing population infection surveillance programs with Bioiq.
Guilford, Conn.-based Butterfly Network Inc. completed its business combination with New York-based Longview Acquisition Corp., a special purpose acquisition company sponsored by an affiliate of Glenview Capital Management LLC. The business combination was approved by Longview's stockholders at its special meeting held on Feb. 12. The transaction resulted in the combined company being renamed to Butterfly Network Inc., with its class A common stock and warrants to commence trading on the New York Stock Exchange on Feb. 16, under the symbols BFL and BFLY W, respectively. Butterfly received approximately $589 million prior to transaction fees, including approximately $414 million of cash held in Longview's trust account and $175 million from private placement (PIPE) investors, including Eldridge, Fidelity Management & Research Co. LLC, Glenview, Ridgeback, Tenet Healthcare Corp., UPMC Enterprises, and Wellington Management. In addition, Butterfly's current management and existing equity holders have rolled 100% of their equity into the combined company. J.P. Morgan Securities LLC acted as financial advisor to Butterfly. UBS Investment Bank acted as financial advisor to Longview as well as the exclusive placement agent for the PIPE. UBS Investment Bank and Cowen acted as capital markets advisors to Longview, and originally underwrote the IPO of Longview in May 2020. Butterfly created a handheld, single-probe whole-body ultrasound system using its Ultrasound-on-Chip semiconductor technology.
C2dx Inc., of Schoolcraft, Mich., said it has acquired the T/Pump product line from Stryker Corp., of Kalamazoo, Mich. Financial terms of the transaction were not disclosed.
Coopersurgical, of Trumbull, Conn., a wholly owned subsidiary of Coopercompanies Inc., reported a multiyear, strategic collaboration, commencing this month, with Virtus Health Ltd., of Greenwich, New South Wales, Australia, to drive innovation, digitalization and advancement in fertility treatment.
Dublin-based Ers Genomics Ltd. and Barcelona-based Zeclinics, a contract research organization using zebrafish to carry out services focused on analyzing the safety, efficacy and biomedical relevance of new compounds, reported a nonexclusive license agreement granting Zeclinics access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
Luxembourg-based Eurofins reported the launch of its CE-marked GSD Novaprime SARS-CoV-2 Direct RT-PCR. Additionally, the company’s GSD Novaprime SARS-Cov-2 (COVID-19) has been successfully validated for pharynx gargle and saliva samples.
Eurofins Scientific, of Luxembourg, said it has brought together its U.K. laboratories across multiple disciplines to facilitate increased direct-to-consumer COVID-19 testing. Eurofins Forensics, Eurofins Clinical Diagnostics and Eurofins Food & Water Testing will facilitate up to 350,000 tests per week, made available to the general public via home test kits.
Halberd Corp., of Jackson Center, Pa., is collaborating with Greenbioaz Inc., of Chandler, Ariz., to conduct laboratory testing of Halberd’s patent-pending radiofrequency (RF) extracorporeal treatment to eliminate infectious disease pathogens. The methodology entails treating bodily fluids with an antibody-metallic moiety conjugate, which targets a specific pathogen such as SARS-CoV-2 while extracorporeally exposing bodily fluids to a specific RF wavelength.
Cincinnati-based Kroger Health, the health care division of The Kroger Co., said it plans to offer the smartphone-enabled, at-home COVID-19 Rapid Antigen Test Kit by Gauss Surgical, of Menlo Park, Calif., to patients nationwide.
Lifelabs LP, of Etobicoke, Ontario, and Multiplex Genomics, a recent spinoff from the Centre for Biodiversity Genomics at the University of Guelph, Ontario, have forged a strategic alliance to increase COVID-19 testing capability and track COVID-19 variants. Through this joint effort, Lifelabs and Multiplex Genomics will be able to analyze 20,000 COVID-19 samples a day, with plans to grow to 50,000 by mid-2021.
Baltimore, Md.-based Machine Sense LLC said its Feverwarn business has launched new Opx scanning technology enabling customers to optimize temperature scanning performance in varying weather conditions.
Dublin-based Medtronic plc said that spine surgeons across the U.S. have completed the first procedures utilizing the newly cleared navigated disc prep, interbodies and Midas Rex high-speed drills with the Mazor robotic guidance system.
Cincinnati-based Meridian Biosciences Inc. said the U.S. FDA has requested additional information on its SARS-CoV-2 molecular diagnostic test on its Revogene platform pursuant to an emergency use authorization application. The company plans to submit a response to the agency today. Meridian said it has elected to place shipments of the SARS-CoV-2 test kits on hold while it works with the FDA.
Microbix Biosystems Inc., of Mississauga, Ontario, has entered an agreement with Oneworld Accuracy Inc., of Vancouver, British Columbia, to distribute Microbix’s quality assessment products on a nonexclusive basis across Africa, in Canada and in the U.S.
Boston-based Myomo Inc., a wearable medical robotics company focused on neurological disorders and upper-limb paralysis, said that Techniker Krankenkasse, Germany’s largest statutory health insurance company, now approves reimbursement for Myopro on a case-by-case basis.
Padova, Italy-based Patchai and Roche Italia, of Monza, Italy, part of Roche Group AG, reported an agreement regarding the Patchai for Smart Health Companion (SHC) platform for oncology patients. SHC is a modular platform used to deliver the Roche patient support program called Smart Health Companion and currently is available in Italy for patients with haemato-oncological conditions.
Progressive Care Inc., a personalized health care services and technology company based in Hallandale Beach, Fla., has teamed up with Eagleforce Health LLC, of Herndon, Va., to integrate its telehealth platform and develop a platform for the company’s digital passport for COVID-19 testing and vaccination results.
Cambridge, U.K.-based Spt Labtech Ltd., a company that develops automated instrumentation and consumables for life science applications, has acquired Biomicrolab Inc., of Concord, Calif., a robotics automation provider for life science laboratories. Terms of the deal were not disclosed.
Netanya, Israel-based Theranica Bio-Electronics Ltd. has signed a Federal Supply Schedule agreement with the U.S. Department of Veterans Affairs to make its wearable Nerivio acute migraine therapeutic device available to veterans.
Xphyto Therapeutics Corp., of Vancouver, British Columbia, and its exclusive diagnostics development partner, 3a-diagnostics GmbH, of Frickenhausen, Germany, said they have completed the European CE-IVD application for the rapid point-of-care SARS-CoV-2 RT-PCR Test system. 3a expects ISO 13485 approval as a medical device manufacturer by late February and European regulatory approval as a commercial in vitro diagnostics device for COVID-ID Lab by early March.